Wednesday, March 20, 2019 10:46:19 AM
AngioSoma, Inc. Announces Selection of Regulatory Firm for Flagship Drug
HOUSTON, TX, June 18, 2018 (GLOBE NEWSWIRE) -- AngioSoma, Inc. (SOAN) is excited to announce that we have identified a regulatory firm who can assist taking our patented flagship drug, Liprostin(TM), through the FDA approval process. The regulatory firm will begin with a presubmission meeting with the FDA biologic group to obtain a regulatory strategy consensus with the FDA for authority to proceed. The objective is agreement for the protocol for the third and final clinical trial.
Our patented drug, Liprostin(TM), has completed the Phase II Clinical Study for treatment of Peripheral Arterial Disease (PAD) that often results in amputation as treatment. Liprostin(TM) is believed to reduce walking pain, treat diabetic ulcerations and reduce inflammation.
ABOUT ANGIOSOMA, INC.
AngioSoma, Inc. (www.angiosoma.com), a Nevada corporation based in Houston, Texas, markets our Somaceuticals(TM) line of health supplements. Our innovative supplements cover three industry segments: nutraceuticals, cosmeceuticals, and pharmaceuticals, all dedicated to improving the mental and physical wellbeing of men and women. Alex Blankenship, CEO, has expressed her appreciation for the valuable contribution of our chosen regulatory firm for developing and implementing the strategy for the FDA approval process.
CONTACT
Alex Blankenship
AngioSoma, Inc.
Alex@AngioSoma.com
> Dow Jones Newswires
June 18, 2018 11:44 ET (15:44 GMT)
$SOAN
Recent GSTC News
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/17/2024 08:05:07 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 02/15/2024 04:33:13 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 01/19/2024 10:13:47 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 01/02/2024 09:21:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 05:32:02 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/17/2023 08:01:04 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 08:31:39 PM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM